British drugmaker GlaxoSmithKline will resume payments to doctors for promotion of its medicines in certain situations, stepping away from a 2013 pledge which had banned the practice.
GSK will now allow payments to healthcare professionals who speak about its products in promotional settings, as well as pay for travel costs for doctors outside the U.S. to attend GSK-organized events. These changes will only take effect for certain products in select countries, the pharma said Tuesday.
The policy shift will put Glaxo more in line with industry practice, even as marketing efforts by drugmakers continue to come under scrutiny from regulators and lawmakers.
